Grote Ludger, Anderberg Carl-Peter, Friberg Danielle, Grundström Gert, Hinz Kerstin, Isaksson Göran, Murto Tarmo, Nilsson Zarita, Spaak Jonas, Stillberg Göran, Söderberg Karin, Tegelberg Åke, Theorell-Haglöw Jenny, Ulander Martin, Hedner Jan
Center for Sleep and Wake Disorders, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, 405 30 Gothenburg, Sweden.
Pulmonary Medicine, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Diagnostics (Basel). 2023 Mar 20;13(6):1179. doi: 10.3390/diagnostics13061179.
This paper describes the development of "Swedish Guidelines for OSA treatment" and the underlying managed care process. The Apnea Hypopnea Index (AHI) is traditionally used as a single parameter for obstructive sleep apnea (OSA) severity classification, although poorly associated with symptomatology and outcome. We instead implement a novel matrix for shared treatment decisions based on available evidence.
A national expert group including medical and dental specialists, nurses, and patient representatives developed the knowledge-driven management model. A Delphi round was performed amongst experts from all Swedish regions (N = 24). Evidence reflecting treatment effects was extracted from systematic reviews, meta-analyses, and randomized clinical trials.
The treatment decision in the process includes a matrix with five categories from a "very weak"" to "very strong" indication to treat, and it includes factors with potential influence on outcome, including (A) OSA-related symptoms, (B) cardiometabolic comorbidities, (C) frequency of respiratory events, and (D) age. OSA-related symptoms indicate a strong incitement to treat, whereas the absence of symptoms, age above 65 years, and no or well-controlled comorbidities indicate a weak treatment indication, irrespective of AHI.
The novel treatment matrix is based on the effects of treatments rather than the actual frequency of respiratory events during sleep. A nationwide implementation of this matrix is ongoing, and the outcome is monitored in a prospective evaluation by means of the Swedish Sleep Apnea Registry (SESAR).
本文描述了《瑞典阻塞性睡眠呼吸暂停治疗指南》的制定过程以及相关的管理式医疗流程。传统上,呼吸暂停低通气指数(AHI)被用作阻塞性睡眠呼吸暂停(OSA)严重程度分类的单一参数,尽管它与症状和治疗结果的关联性较差。我们转而基于现有证据实施了一种用于共同治疗决策的新型矩阵。
一个由医学和牙科专家、护士及患者代表组成的全国性专家组开发了这种基于知识的管理模型。在瑞典所有地区的专家(N = 24)中进行了一轮德尔菲调查。从系统评价、荟萃分析和随机临床试验中提取反映治疗效果的证据。
该流程中的治疗决策包括一个矩阵,有从“非常弱”到“非常强”的五类治疗指征,并且包含对治疗结果有潜在影响的因素,包括(A)OSA相关症状、(B)心血管代谢合并症、(C)呼吸事件频率以及(D)年龄。OSA相关症状表明强烈的治疗诱因,而无症状、年龄在65岁以上以及无合并症或合并症得到良好控制则表明治疗指征较弱,无论AHI如何。
这种新型治疗矩阵基于治疗效果而非睡眠期间呼吸事件的实际频率。该矩阵正在全国范围内实施,其结果通过瑞典睡眠呼吸暂停登记处(SESAR)进行前瞻性评估监测。